Aerobic Exercise in Women With Systemic Lupus Erythematosus
NCT03186794 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2022-05-10
Summary
Background:
As many as 1.5 million Americans are living with systemic lupus erythematosus (Lupus). Lupus makes people very tired. It also makes it hard for people to be physically active. Studies have shown that aerobic exercise training helps people with heart or lung illnesses be less tired and more active. Researchers want to use an exercise training program on people with Lupus to see if it has the same results.
Objectives:
To find out if aerobic exercise helps people with Lupus be less tired and more active.
Eligibility:
Women ages 21-80 who have Lupus and are not physically active.
Design:
Participants will be screened with a medical history and physical exam. They will have heart and lung tests, as well as blood and urine tests. They will also answer questions about their quality of life and take a test that measures lupus activity.
The study will last 14-16 weeks.
For the first two study visits, participants will do treadmill exercise tests and answer more quality of life questions. For these treadmill tests, participants will wear sensors, a mask, or a mouthpiece while they exercise.
Participants will then begin exercise training, 3 times a week for 12 weeks. At each of these visits, they will walk very fast for 30 minutes on a track or a treadmill. Each visit will last about 1 hour.
At the halfway point of the study, participants will repeat some of the screening tests. This visit will last about 3 hours.
At the end of the study, participants will repeat the screening tests. They will also repeat the treadmill exercise tests.
Conditions
- Systemic Lupus Erythematosus
- Lupus
- Autoimmune Disease
- Rheumatic Disease
Interventions
- OTHER
-
Treadmill exercise training
30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
lead NIH
Principal Investigators
-
Leighton Chan, M.D. · National Institutes of Health Clinical Center (CC)
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 21 Years
- Max Age
- 80 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-22
- Primary Completion
- 2021-02-25
- Completion
- 2021-02-25
Countries
- United States
Study Locations
More Related Trials
-
Exercise and Systemic Lupus Erythematosus
NCT01515163 ·Status: UNKNOWN ·Phase: NA
-
Lupus Intervention for Fatigue Trial
NCT02653287 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effects of High-intensity Interval Training in Patients With Systemic Lupus Erythematosus
NCT06166199 ·Status: RECRUITING ·Phase: NA
-
Respiratory Function, Physical Activity and Fatigue in SLE
NCT07193745 ·Status: COMPLETED
-
Systemic Lupus Erythematosus
NCT05984316 ·Status: RECRUITING ·Phase: NA
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
Development and Evaluation of Modified Yoga in Systemic Lupus Erythematosus (SLE)
NCT01176643 ·Status: COMPLETED ·Phase: NA
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
NCT06032923 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus
NCT05261529 ·Status: UNKNOWN ·Phase: NA
-
Water-based Liuzijue Exercise on Childhood-onset Systemic Lupus Erythematosus
NCT07024082 ·Status: COMPLETED ·Phase: NA
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
Fatigue in Lupus Intervention Programmes (FLIP)
NCT06308770 ·Status: RECRUITING ·Phase: NA
-
Lupus Education Alliance Program
NCT05243875 ·Status: TERMINATED ·Phase: NA
-
Reducing Depressive Symptoms in Systemic Lupus Erythematosus
NCT01120652 ·Status: COMPLETED ·Phase: NA
-
Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
NCT02822989 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT03724916 ·Status: COMPLETED ·Phase: PHASE1
-
Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
NCT05426902 ·Status: COMPLETED ·Phase: NA
-
Rituximab Objective Outcome Measures Trial in SLE
NCT03054259 ·Status: UNKNOWN ·Phase: PHASE2
-
Exercise and Nutrition Recommendations for Patients Using Glucocorticoids (ENRG)
NCT05090189 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2
-
Zostavax in Systemic Lupus Erythematosus
NCT01474720 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
NCT06710717 ·Status: RECRUITING ·Phase: PHASE1
-
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
NCT02338999 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Anti-CD20 in Systemic Lupus Erythematosus
NCT00036491 ·Status: COMPLETED ·Phase: PHASE1/PHASE2